Special Issue

Topic: Immunotherapy and Immunotherapy Biomarkers for Hepatocellular Carcinoma

A Special Issue of Hepatoma Research

ISSN 2454-2520 (Online) 2394-5079 (Print)

Submission deadline: 15 Nov 2022

Guest Editor(s)

Sandi Alexander Kwee, MD, PhD
Associate Professor, Clinical and Translational Sciences Program, University of Hawaii Cancer Center, and John A. Burns School of Medicine, University of Hawaii, Honolulu, USA.

Special Issue Introduction

Immune checkpoint inhibitor agents are now globally available for use in first-line or second-line treatment of unresectable hepatocellular carcinoma (HCC). However, objective responses to these agents occur in only a small fraction of patients, and a reliable tissue, serum, or imaging biomarker for predicting therapeutic response has yet to be identified. The pathways and mechanisms underlying the development of immunotherapy resistance are also poorly understood, and clinically, there still exists a need to further define the role of biomarkers for immune checkpoint inhibitors used alone or in combination with other therapies including liver-directed therapies. For this Special Issue on immunotherapy and immunotherapy biomarkers in HCC, we include original articles, perspectives, and reviews of clinical and pre-clinical research that support the goal of improving HCC immunotherapy effectiveness and precision.

Submission Deadline

15 Nov 2022

Submission Information

For Author Instructions, please refer to https://oaepublish.com/hr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=405
Submission Deadline: 15 Nov 2022
Contacts: Victoria Lee, Assistant Editor, editor_Victoria@hrjournal.net

Published Articles

Open Access Editorial
Open Access Review

Immunotherapy and immunotherapy biomarkers for hepatocellular carcinoma

Hepatoma Res 2021;7:18.
DOI: 10.20517/2394-5079.2020.118
Published on: 8 Mar 2021
Open Access Review
Open Access Review

Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus

Hepatoma Res 2020;6:68.
DOI: 10.20517/2394-5079.2020.58
Published on: 11 Oct 2020
Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)


All published articles are preserved here permanently:



All published articles are preserved here permanently: